Valuation: Rapport Therapeutics, Inc.

Market Cap 1.94B 1.69B 1.6B 1.45B 2.71B 186B 2.73B 19.11B 7.37B 94.51B 7.28B 7.12B 304B P/E 2026 *
-9.99x
P/E 2027 * -8.25x
Enterprise Value 1.61B 1.4B 1.32B 1.2B 2.25B 154B 2.26B 15.86B 6.12B 78.46B 6.04B 5.91B 252B EV / Sales 2026 *
80.4x
EV / Sales 2027 * -
Free-Float
96.1%
Yield 2026 *
-
Yield 2027 * -
1 day-3.58%
1 week-7.27%
Current month-16.89%
1 month-17.47%
3 months+8.33%
6 months+52.76%
Current year+33.32%
1 week 40.28
Extreme 40.285
44.9
1 month 40.28
Extreme 40.285
52.93
Current year 25.21
Extreme 25.21
52.93
1 year 23.75
Extreme 23.75
52.93
3 years 6.43
Extreme 6.43
52.93
5 years 6.43
Extreme 6.43
52.93
10 years 6.43
Extreme 6.43
52.93
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 61 01/01/2023
Chief Executive Officer 48 01/02/2023
Director of Finance/CFO 58 01/11/2023
Director TitleAgeSince
Director/Board Member 61 23/08/2023
Director/Board Member 48 01/03/2023
Director/Board Member 54 01/02/2022
Date Insider Type Main position Quantity % Market Cap. Importance
08/09/26 Sell

Chief Executive Officer

-8,210 0.0171%
25/08/26 Sell

Executive/Senior Manager

-37,000 0.0774%
25/08/26 Sell

Chief Executive Officer

-18,921 0.0396%
Change 5-day change 1-year change 3-year change Capi.($)
-3.58%-7.27%+47.90% - 1.94B
+0.11%+2.71%+0.33%+28.59% 46.28B
-1.12%+1.78%+40.07%+27.26% 43.85B
-3.04%-6.29%+322.27%+517.36% 40.93B
-0.74%+1.25%+2.32%+67.94% 39.9B
-0.50%+0.67%+11.79%+40.51% 29.5B
-0.46%+4.22%+21.99%+124.21% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.15%+38.93% 15.22B
-3.14%+31.91%-10.60% - 14.05B
Average -1.25%+2.66%+50.91%+120.69% 26.43B
Weighted average by Cap. -1.04%+1.81%+64.56%+130.23%

Financials

2026 *2027 *
Net sales 20M 17.44M 16.47M 14.95M 28.02M 1.92B 28.13M 197M 76.12M 976M 75.13M 73.46M 3.14B -
Net income -194M -169M -160M -145M -272M -18.63B -273M -1.91B -739M -9.47B -729M -713M -30.47B -252M -220M -208M -189M -354M -24.22B -355M -2.49B -961M -12.31B -948M -927M -39.62B
Net Debt -329M -287M -271M -246M -461M -31.58B -463M -3.25B -1.25B -16.06B -1.24B -1.21B -51.66B -477M -416M -393M -356M -668M -45.74B -671M -4.7B -1.81B -23.26B -1.79B -1.75B -74.83B
Logo Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.
Employees
84
Date Price Change Volume
18/09/26 $40.45 -3.58% 998,058
17/09/26 $41.95 +1.35% 397,300
16/09/26 $41.39 -3.02% 387,025
15/09/26 $42.68 -3.00% 189,312
14/09/26 $44.00 +0.87% 196,927
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
40.45USD
Average target price
62.88USD
Spread / Average Target
+55.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RAPP Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!